Skip to main content

ADMA Biologics, Inc.

corporate_fare Company Profile

ADMA Biologics, Inc.

ADMA·NASDAQ·Life Sciences·CIK 0001368514

ADMA Biologics is a U.S.-based commercial biopharmaceutical company that manufactures, markets, and develops specialty biologics. The company focuses on treating immunodeficient patients susceptible to infection and individuals at risk for specific infectious diseases, including immune-compromised individuals with underlying immune deficiency disorders or those who are medically immune-suppressed. Through its ADMA BioManufacturing business segment, ADMA Biologics has three FDA-approved products that are currently marketed and commercially available. These include ASCENIV (Immune Globulin Intravenous, Human - slra 10% Liquid), an Intravenous Immune Globulin (IVIG) product approved in April 2019, with first commercial sales in October 2019, for treating Primary Humoral Immunodeficiency in adults and adolescents. Another product is BIVIGAM, an IVIG product approved in May 2019, with commercial sales starting in August 2019, for treating Primary Immunodeficiency in adults and pediatric patients aged two years and older. The third product is Nabi-HB (Hepatitis B Immune Globulin, Human), indicated for treating acute exposure to blood containing HBsAg and other listed Hepatitis B exposures. The company is also developing plasma-derived therapeutics, including a product based on U.S. Patent Nos. 10,259,865 and 11,084,870, related to methods for treating and preventing S. pneumoniae infection using an immunoglobulin with standardized antibodies. A pilot-scale batch of this product has been produced, and animal studies are underway.

ADMA Biologics, Inc. (NASDAQ:ADMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ADMA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • ADMA Biologics Reports Record 2025 Financial Results, Strong 2026-2029 Guidance, and Smooth CFO Transition
  • ADMA Biologics Raises 2026 Guidance, Projects Strong Long-Term Growth to $1.1B Revenue by 2029

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$510.17M
Net Income
$146.93M
Diluted EPS
$0.60
Op. Cash Flow
$50.4M
Free Cash Flow
$27.82M
Gross Profit
$292.76M
Operating Income
$191.44M
Cash & Equivalents
$87.63M
Total Debt
$72.14M
Debt / Equity
0.15×
Net Margin
28.8%
Shares Outstanding
237.87M sh
Source: 10-K · filed 2026-02-25 · accession 0001140361-26-006815
$13.3 +0.99% today
52-week range · as of 2026-11-04 $7.21 – $20.46
Market cap
$2.92B
Volume
2.4M (0.7× avg)
3-mo avg 3.7M
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ADMA - Filings & News (Page 2)

ADMA
Feb 25, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.05
Real-time Price: $13.30 info
Change: -$2.75 (-17%) info
Market Cap: $2.922B info
ADMA
Jan 12, 2026, 8:20 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.14
Real-time Price: $13.30 info
Change: -$4.84 (-27%) info
Market Cap: $2.922B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets